<DOC>
	<DOCNO>NCT01260714</DOCNO>
	<brief_summary>This phase I trial study best dose azacitidine see well work mitoxantrone hydrochloride etoposide treat old patient acute myeloid leukemia low chance respond treatment high risk return ( poor prognosis ) . Drugs use chemotherapy , azacitidine , mitoxantrone hydrochloride , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Azacitidine , Mitoxantrone Hydrochloride , Etoposide Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine high tolerate dose two dose schedule azacitidine combine mitoxantrone ( mitoxantrone hydrochloride ) etoposide ( A-NOVE ) chemotherapy poor prognosis old patient acute myeloid leukemia ( AML ) . II . To evaluate toxicity regimen . SECONDARY OBJECTIVES : I . To determine complete response ( CR ) rate use regimen . II . To evaluate change topoisomerase II activity , deoxyribonucleic acid ( DNA ) methylation DNA expression array leukemia cell azacitidine treatment , correlate change responses A-NOVE chemotherapy . III . To evaluate relapse-free survival ( RFS ) overall survival ( OS ) patient receive post-remission consolidation A-NOVE patient achieve CR . ( OS follow-up discontinue 08/07/2014 ) OUTLINE : This dose-escalation study azacitidine . Patients receive induction therapy comprise azacitidine subcutaneously ( SC ) daily ( QD ) day 1-7 , mitoxantrone hydrochloride IV 30 minute , etoposide IV 1 hour day 4-8 . Patients may receive 2 additional course treatment re-induction consolidation therapy begin 35-60 day start previous course . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Acute myeloid leukemia ( AML ) define World Health Organization ( WHO ) criterion , subtype , de novo secondary , except acute promyelocytic leukemia ( APL ) One following : Previously untreated , adverserisk cytogenetics , include one following : Complete partial deletion chromosome 7 Complete partial deletion chromosome 5 At least 3 numerical structural abnormality , ( 15 ; 17 ) , ( 8 ; 21 ) inv ( 16 ) variant 11q23 abnormality Inv ( 3 ) variant ( 3:3 ) Previously untreated , transform prior myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) CML Persistent leukemia follow one cycle 3+7 induction therapy ( cytarabine plus either daunorubicin idarubicin ) , cytogenetic risk group Left ventricular ejection fraction ( LVEF ) &gt; 50 % base multi gated acquisition scan ( MUGA ) scan 2dimensional ( 2D ) echocardiogram Serum creatinine = &lt; 1.5 x upper limit normal ( ULN ) Serum bilirubin = &lt; 1.5 x ULN Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( Karnofsky &gt; = 60 % ) Patients high initial white blood cell ( WBC ) WBC reduce 50 x 10^9/L hydroxyurea , minimize risk leukostasis relatedcomplications ; hydroxyurea permit 24 hour prior start azacitidine Men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; men father child participate study Ability understand willingness sign write informed consent document Patients chemotherapy , radiotherapy investigational agent within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier Patients receive prior radiation great 3000 cGy marrow produce area Patients may receive investigational agent Patients active central nervous system ( CNS ) leukemia ; prior CNS leukemia permit provided cerebrospinal fluid clear evidence active CNS leukemia Prior therapy AML decitabine , azacitidine , mitoxantrone , etoposide Prior therapy azacitidine decitabine preexist MDS History allergic reaction attribute decitabine , azacitidine , etoposide , mitoxantrone , compound similar chemical biologic composition Uncontrolled intercurrent illness include , limited , active uncontrolled infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Human immunodeficiency virus ( HIV ) positive patient cluster differentiation ( CD ) count less 500/mm^3 and/or history HIV/acquired immune deficiency syndrome ( AIDS ) relate complication exclude study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>